#USA #New England Biolabs #Ipswich #seqWell #TnX Transposase

New England Biolabs and seqWell Launch TnX Transposase

In a significant development for genomic research, New England Biolabs (NEB) has partnered with seqWell to introduce the TnX Transposase (Unloaded). This launch not only signifies a strategic alliance but also showcases both companies' commitment to advancing molecular biology tools. The TnX Transposase is designed for next-generation sequencing (NGS) library preparation, enhancing efficiency and flexibility in genomic workflows.

About the Partnership

The collaboration combines NEB's extensive expertise in enzyme development with seqWell's innovative genomic solutions. As part of the agreement, NEB has secured co-exclusive rights to market TnX Transposase, allowing it to manufacture the product and include it in its own kits. This partnership is designed to streamline the process of nucleic acid fragmentation, simultaneously facilitating adaptor insertion in a single step, thus reducing overall processing time.

Isaac Meek, NEB’s Director of Business Development, expressed enthusiasm about the partnership, stating, “We're excited to provide researchers with a highly reproducible transposase that gives them freedom over adaptor design.” The flexibility of the TnX Transposase allows for the assembly of custom transposomes tailored to specific research needs, accommodating various methodologies.

The TnX Transposase Technology

TnX Transposase (Unloaded) is an engineered variant that does not come preloaded with DNA adaptors. This design empowers researchers to utilize their preferred mosaic-end oligonucleotides, promoting a customizable experience in genomic research. This unique feature is particularly beneficial for developers working on bespoke assays, single-cell workflows, and innovative genomic methods.

Joe Mellor, Chief Scientific Officer at seqWell, highlighted the importance of the partnership by stating, “NEB's reputation for quality and reliability makes them the ideal partner to bring TnX to a wider audience.” The combined expertise aims to address challenges associated with lot variability, a common concern in genomic studies with unloaded Tn5 transposases.

As researchers strive for high-quality, versatile tools in their work, the collaboration between NEB and seqWell aims to fill a crucial gap in genomic technology. The TnX Transposase's development approach is grounded in a commitment to advancing research capabilities in molecular diagnostics and nucleic-acid vaccines, crucial for today's scientific landscape.

Availability and Further Information

TnX Transposase (Unloaded) is now available for purchase from NEB, accompanied by comprehensive loading and reaction protocols to assist researchers in utilizing the product effectively. More detailed product specifications can be found on the official NEB website at www.neb.com/M2623.

For those looking for TnX-based library preparation kits, seqWell's offerings are available via their website at www.seqwell.com, where researchers can access a complete suite of solutions tailored to genomic applications.

About the Companies

New England Biolabs

For over five decades, NEB has been at the forefront of enzyme discovery and production for molecular biology. With a robust commitment to supporting scientific advancements, NEB provides a diverse product portfolio and invests in both basic and applied research, helping to propel the life sciences forward. Headquartered in Ipswich, Massachusetts, NEB operates globally, maintaining a deep commitment to the scientific community.

seqWell

SeqWell's mission revolves around creating scalable genomic technologies that simplify execution workflows for researchers. Their TnX® transposase technology aims to bolster scalability and enhance the performance demands of genomic research, making groundbreaking discoveries possible as sequencing technology evolves.

This partnership is not just a milestone for both companies; it reflects a broader commitment to equipping the scientific community with top-tier resources, ensuring that groundbreaking genomic research continues to flourish. With NEB and seqWell joining forces, researchers have high hopes for the implications of the TnX Transposase in various cutting-edge fields.